Dose reduction recommendations |
In October 2013, the following specific recommendations were formulated after discussions with the US FDA on evolving observations of arterial occlusive events in patients treated with ponatinib: |
All chronic phase chronic myeloid leukemia (CP-CML) patients on study who already had achieved major cytogenetic response (MCyR) should have had their dose reduced to 15 mg daily, unless, in the judgment of the investigator, the benefit/risk analysis, taking into account the patient's disease characteristics, BCR::ABL mutation status, and the patient's cardiovascular risk justified treatment with a higher dose |
All CP-CML patients on study who had not yet achieved MCyR should have had their dose reduced to 30 mg daily, unless, in the judgment of the investigator, the benefit/risk analysis, taking into account the patient's disease characteristics, BCR::ABL mutation status, and the patient's cardiovascular risk justified treatment with a higher dose |
All acute phase chronic myeloid leukemia (AP-CML), blast phase chronic myeloid leukemia (BP-CML), and Ph+ acute lymphoblastic leukemia (ALL) patients on study should have had their dose reduced to 30 mg daily, unless, in the judgment of the investigator, the benefit/risk analysis, taking into account the patient's disease characteristics, BCR::ABL mutation status, and the patient's cardiovascular risk justified treatment with a higher dose |
All patients who lost response at a lower dose may have their dose escalated (up to a maximum of 45 mg daily) as long as the dose was not lowered as a result of an adverse event (AE) |